MPIA
ZVRA icon

Mountain Pacific Investment Advisers’s Zevra Therapeutics ZVRA Stock Holding History

Mountain Pacific Investment Advisers’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-665
Closed -$43K – 117
2017
Q4 		$43K Buy
+665
New +$40.1K ﹤0.01% 108

Other funds holding ZVRA

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
IG
ING Group Amsterdam, Netherlands $16.4B AUM 34.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mountain Pacific Investment Advisers's ZVRA Position: Q1 2018 in Review

Mountain Pacific Investment Advisers sold out of Zevra Therapeutics (ZVRA) in Q1 2018, closing a stake of 665 shares — an estimated $43K sold.

Mountain Pacific Investment Advisers first reported a position in ZVRA in Q4 2017 and held it in 1 quarter. The position peaked at $43K in Q4 2017. 34 funds tracked by Wall St. Rank hold ZVRA as of Q1 2018.

  • Mountain Pacific Investment Advisers reported no remaining Zevra Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Mountain Pacific Investment Advisers sold 665 Zevra Therapeutics shares in Q1 2018, an estimated $43K.
  • Mountain Pacific Investment Advisers first reported a position in Zevra Therapeutics in Q4 2017 and held it in 1 quarter.
  • Mountain Pacific Investment Advisers's Zevra Therapeutics position peaked at $43K in Q4 2017.
  • 34 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2018.

Based on Mountain Pacific Investment Advisers's 13F filing for Q1 2018, filed 30 Apr 2018.